Dionex (DNEX) Enters Into Agreement With ESA Biosciences to Acquire the Assets of ESA Biosciences Tools Business Unit; Dionex Anticipates the Transaction will Generate Additional Revenue of $12-$15 Million  
9/16/2009 8:52:57 AM

Bookmark and Share

SUNNYVALE, Calif., Sept. 16, 2009 (GLOBE NEWSWIRE) -- Dionex Corporation (Nasdaq:DNEX), a leading provider of innovative liquid chromatography analysis systems, has entered into an Asset Purchase Agreement with ESA Biosciences, a wholly owned subsidiary of Magellan Biosciences, Inc., to purchase ESA Biosciences HPLC products, HPLC clinical assays, laboratory services and related assets.